Afuco™ Anti-ACVRL1 ADCC Therapeutic Antibody (Ascrinvacumab), ADCC Enhanced

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to ACVRL1. Ascrinvacumab is a human monoclonal antibody that can be potentially used in the treatment of Mesothelioma, pleural malignant, Hepatocellular carcinoma (HCC).
Supplier Creative Biolabs
Product # AFC-TAB-003ML
Pricing Inquiry
Host Human
Target ACVRL1
Species Reactivity Human
Type ADCC enhanced antibody
Applications ELISA, IHC, FC, IP, IF, Inhib
Storage Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Feedback